The inositol 1,4,5-trisphosphate receptor (IP 3 R) in the endoplasmic reticulum mediates calcium signaling that impinges on intracellular processes. IP 3 Rs are allosteric proteins comprising four subunits that form an ion channel activated by binding of IP 3 at a distance. Defective allostery in IP 3 R is considered crucial to cellular dysfunction, but the specific mechanism remains unknown. Here we demonstrate that a pleiotropic enzyme transglutaminase type 2 targets the allosteric coupling domain of IP 3 R type 1 (IP 3 R1) and negatively regulates IP 3 R1-mediated calcium signaling and autophagy by locking the subunit configurations. The control point of this regulation is the covalent posttranslational modification of the Gln2746 residue that transglutaminase type 2 tethers to the adjacent subunit. Modification of Gln2746 and IP 3 R1 function was observed in Huntington disease models, suggesting a pathological role of this modification in the neurodegenerative disease. Our study reveals that cellular signaling is regulated by a new mode of posttranslational modification that chronically and enzymatically blocks allosteric changes in the ligand-gated channels that relate to disease states.
The inositol 1,4,5-trisphosphate receptor (IP 3 R) in the endoplasmic reticulum mediates calcium signaling that impinges on intracellular processes. IP 3 Rs are allosteric proteins comprising four subunits that form an ion channel activated by binding of IP 3 at a distance. Defective allostery in IP 3 R is considered crucial to cellular dysfunction, but the specific mechanism remains unknown. Here we demonstrate that a pleiotropic enzyme transglutaminase type 2 targets the allosteric coupling domain of IP 3 R type 1 (IP 3 R1) and negatively regulates IP 3 R1-mediated calcium signaling and autophagy by locking the subunit configurations. The control point of this regulation is the covalent posttranslational modification of the Gln2746 residue that transglutaminase type 2 tethers to the adjacent subunit. Modification of Gln2746 and IP 3 R1 function was observed in Huntington disease models, suggesting a pathological role of this modification in the neurodegenerative disease. Our study reveals that cellular signaling is regulated by a new mode of posttranslational modification that chronically and enzymatically blocks allosteric changes in the ligand-gated channels that relate to disease states.
allosteric regulation | IP 3 receptor | isopeptide bond | transamidation | deamidation L igand-gated ion channels function by allostery that is the regulation at a distance; the allosteric coupling of ligand binding with channel gating requires reversible changes in subunit configurations and conformations (1) . Inositol 1,4,5-trisphosphate receptors (IP 3 Rs) are ligand-gated ion channels that release calcium ions (Ca 2+ ) from the endoplasmic reticulum (ER) (2, 3) . IP 3 Rs are allosteric proteins comprising four subunits that assemble a calcium channel with fourfold symmetry about an axis perpendicular to the ER membrane. The subunits of three IP 3 R isoforms (IP 3 R1, IP 3 R2, and IP 3 R3) are structurally divided into three domains: the IP 3 -binding domain (IBD), the regulatory domain, and the channel domain (3) (4) (5) (6) . Fitting of the IBD X-ray structures (7, 8) to a cryo-EM map (9) indicates that the IBD activates a remote Ca 2+ channel by allostery (8) ; however, the current X-ray structure only spans 5% of each tetramer, such that the mechanism underlying allosteric coupling of the IBD to channel gating remains unknown.
The IP 3 R in the ER mediates intracellular calcium signaling that impinges on homeostatic control in various subsequent intracellular processes. Deletion of the genes encoding the type 1 IP 3 R (IP 3 R1) leads to perturbations in long-term potentiation/ depression (3, 10, 11) and spinogenesis (12) , and the human genetic disease spinocerebellar ataxia 15 is caused by haploinsufficiency of the IP 3 R1 gene (13) (14) (15) . Dysregulation of IP 3 R1 is also implicated in neurodegenerative diseases including Huntington disease (HD) (16) (17) (18) ) and Alzheimer's disease (AD) (19) (20) (21) (22) . IP 3 Rs also control fundamental cellular processes-for example, mitochondrial energy production (23, 24) , autophagy regulation (24) (25) (26) (27) , ER stress (28) , hepatic gluconeogenesis (29) , pancreatic exocytosis (30) , and macrophage inflammasomes (31) . On the other hand, excessive IP 3 R function promotes cell death processes including apoptosis by activating mitochondrial or calpain pathways (2, 17) . Considering these versatile roles of IP 3 Rs, appropriate IP 3 R structure and function are essential for living systems, and aberrant regulation of IP 3 R closely relates to various diseases.
Several factors such as cytosolic molecules, interacting proteins, and posttranslational modifications control the IP 3 -induced Ca 2+ release (IICR) through allosteric sites in IP 3 Rs. Cytosolic Ca 2+ concentrations strictly control IICR in a biphasic manner with activation at low concentrations and inhibition at higher concentrations. The critical Ca 2+ sensor for activation is conserved among the three isoforms of IP 3 and ryanodine receptors, and this sensor is located in the regulatory domain outside the IBD and the channel domain (32) . A putative ATP regulatory region is deleted
Significance
Reversible and repetitive structural changes are essential for ligand-gated ion channels to mediate biological signaling. The inositol 1,4,5-trisphosphate receptor (IP 3 R) assembles ligandgated ion channels that mediate calcium signaling. IP 3 activates channels at a distance by reversible allosteric changes in the IP 3 R tetramer. Here we show a new mode of posttranslational modification that irreversibly blocks allosteric changes in the IP 3 R. We identified an IP 3 R-modifying enzyme as tissue transglutaminase that inhibits IP 3 R function by locking subunit configurations. This modification chronically impaired calcium signaling and autophagy regulation in living cells, and upregulated modification was observed in Huntington disease models. To our knowledge, this is the first demonstration of transglutaminase-catalyzed posttranslational modification in ligand-gated channel allostery and provides a new framework for enzymatic regulation of allostery.
in opisthotonos mice, and IICR is also regulated by this mutation in the regulatory domain (33) . Various interacting proteins, such as cytochrome c, Bcl-2-family proteins, ataxin-3, huntingtin (Htt) protein, Htt-associated protein 1A (HAP1A), and G-proteincoupled receptor kinase-interacting protein 1 (GIT1), target allosteric sites in the carboxyl-terminal tail (3) (4) (5) . The regulatory domain and the carboxyl-terminal tail also undergo phosphorylation by the protein kinases A/G and B/Akt and contain the apoptotic cleavage sites for the protease caspase-3 (4, 5). These factors allosterically regulate IP 3 R structure and function to control cellular fates; therefore, understanding the allosteric coupling of the IBD to channel gating will elucidate the regulatory mechanism of these factors.
Transglutaminase (TG) catalyses protein cross-linking between a glutamine (Gln) residue and a lysine (Lys) residue via an N e -(γ-glutamyl)lysine isopeptide bond (34, 35) . TG type 2 (TG2) is a Ca 2+ -dependent enzyme with widespread distribution and is highly inducible by various stimulations such as oxidative stress, cytokines, growth factors, and retinoic acid (RA) (34, 35) . TG2 is considered a significant disease-modifying factor in neurodegenerative diseases including HD, AD, and Parkinson's diseases (PD) (34, (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) because TG2 might enzymatically stabilize aberrant aggregates of proteins implicated in these diseases-that is, mutant Htt, β-amyloid, and α-synuclein; however, the causal role of TG2 in Ca 2+ signaling in brain pathogenesis has been unclear. Ablation of TG2 in HD mouse models is associated with increased lifespan and improved motor function (46, 47) . However, TG2 knockout mice do not show impaired Htt aggregation, suggesting that TG2 may play a causal role in these disorders rather than TG2-dependent cross-links in aberrant protein aggregates (47, 48) .
In this study, we discovered a new mode of chronic and irreversible allosteric regulation in IP 3 R1 in which covalent modification of the receptor at Gln2746 is catalyzed by TG2. We demonstrate that up-regulation of TG2 modifies IP 3 R1 structure and function in HD models and propose an etiologic role of this modification in the reduction of neuronal signaling and subsequent processes during the prodromal state of the neurodegenerative disease.
Results
Identification of an IP 3 R1-Modifying Enzyme as TG. In exploring a new allosteric mechanism of IP 3 R tetramers, we developed an agarose gel electrophoresis (AGE) system that can evaluate the large quaternary structure of IP 3 R1 (>1 MDa) ( Fig. 1 A and B) . We found that the incubation of IP 3 R1 with brain cytosol resulted in cross-linking of the IP 3 R1subunits (Fig. 1C) , indicating the existence of an endogenous cross-linking enzyme in the brain. We fractionated the cross-linking activity using chromatography (Fig.  S1 A-C) . The Ca 2+ dependence, elution profile of the activity, and inhibition with cystamine led us to postulate that the crosslinking might be catalyzed by a TG, most likely TG2 (34, 49) .
The direct cross-linking of IP 3 R1 by TG2 was confirmed using purified IP 3 R1 and TG2 (Fig. S1D) . To examine the role of TG2 in the cross-linking of IP 3 R1, we silenced TG2 expression using siRNA in HeLa cells. TG2 knockdown completely abolished the in vitro cross-linking activity in HeLa cell lysates (Fig. 1D) , indicating that TG2 is essential for the cross-linking of IP 3 R1. In contrast, induction of TG2 expression by RA enhanced the crosslinking activity in HeLa cells (Fig. S1E) . Similar cross-linking was observed in living cells including human neuroblastoma (SH-SY5Y) and human glioblastoma (U87-MG) cells (Fig. 1E) . These results support the conclusion that IP 3 R1 is an endogenous substrate of TG2 in living cells.
TG2 Inhibits IP 3 R-Mediated Ca 2+ Release. The AGE analysis revealed that TG2 modifies the IP 3 R1 structure; therefore, we examined whether TG2 regulates IP 3 R1 function. We measured IICR using P2/P3 vesicles and found that purified TG2 inhibited IICR in a dose-dependent manner, without altering ATP-dependent Ca 2+ uptake or the total pool of Ca 2+ ( Fig. 2A) . The inhibitory effects were not observed using boiled TG2 or N-ethylmaleimide (NEM)-treated TG2, indicating that the catalytic activity of TG2 was required for inhibition ( Fig. 2A) .
To elucidate the mechanism by which TG2 negatively regulates channel activity through covalent modification, we used a monoamine compound 5-biotinamido-pentylamine (BP) that contains both primary amine and biotin moieties. BP mimics a Lys residue, and TG2 can enzymaticaly incorporate BP into the Gln residue, which can be traced by horseradish peroxidase (HRP)-conjugated streptavidin. Therefore, we prepared BPcontaining IP 3 R1 using purified TG2 and P2/P3 vesicles (Fig.  2B) . The IICR assay revealed that the BP-containing IP 3 R1 has intact activity (Fig. 2C) , indicating that the structures of both IP 3 -binding and Ca
2+
-permeating domains are not affected by the covalent incorporation of BP molecules. Removal of TG2 and BP followed by the addition of avidin proteins with a neutralized isoelectric point (NeutrAvidin) to the BP-containing IP 3 R1 inhibited IICR in a dose-dependent manner (Fig. 2D) . These results indicate that steric hindrance near the BP-containing Gln residue is important for the allosteric inhibition of IICR.
To examine the inhibitory role of endogenous TG2 in living cells, Ca 2+ imaging was performed using HeLa cells. TG2 silencing significantly enhanced ATP-evoked Ca 2+ release in the Ca 2+ -free condition (Fig. 2E) , indicating that endogenous TG2 inhibits IICR activity in living cells.
TG2 Negatively Regulates IP 3 R-Mediated Autophagy. Our data indicate that TG2 inhibits IP 3 R1 function. To examine the physiological role of this regulation in the cellular functions of IP 3 R1, we studied the role of TG2 and IP 3 R in autophagy. IP 3 R1 regulates autophagy (24) (25) (26) (27) , and TG2 is also thought to regulate autophagy (50, 51) ; however, the interplay between TG2 and IP 3 R1 in autophagy regulation has not been studied. We hypothesized that TG2 affects IP 3 R1-mediated autophagy regulation. To examine autophagy, we used HeLa cells in which both IP 3 R1 and TG2 were expressed dominantly. IP 3 R1 knockdown increases LC3-II (lapidated microtubule-associated protein light chain 3, LC3, an index of autophagy) content without changing the amount of actin (Fig. 3A) , consistent with previous reports (24) (25) (26) (27) . Furthermore, we found that TG2 knockdown had the opposite effect (Fig. 3A) .
To clarify whether IP 3 R1 mediated the TG2-dependent regulation of autophagy, we examined the IP 3 R1 inhibitors xestospongin C (Xest) and 2-aminoethoxydiphenyl borate (2-APB). Xest and 2-APB block the TG2-dependent effect on autophagy (Fig. 3A ) without affecting TG2 levels ( Fig. S2A ), suggesting that TG2 regulates autophagy through IP 3 R1. To confirm this possibility in living cells, we observed the maturation of autophagosomes using a tandem fluorescent LC3 indicator containing both red (RFP) and green (GFP) fluorescent proteins (tfLC3) that distinguishes between autophagosomes and autolysosomes by quenching GFP fluorescence at lysosomal pH (52) . In control siRNA-transfected cells, GFP and RFP puncta were independently distributed, indicating the presence of both autophagosomes and autolysosomes in the cells (Fig. 3B) . However, IP 3 R1 knockdown caused significant accumulation of autophagosomes that were colabeled with GFP and RFP fluorescence, whereas TG2 knockdown yielded predominantly RFP signals, as observed in amino acid deprivation (Fig. 3B) . These results confirm that TG2 and IP 3 R1 have opposing effects in the control of autophagy.
To verify the opposing effects of TG2 and IP 3 R1 on autophagy, we monitored the dynamics of autophagosomes in living cells. Time-lapse imaging of tfLC3 revealed that the autophagosomes in control and TG2 siRNA-transfected cells actively moved inside cells, whereas the altered trafficking of autophagosomes was observed in IP 3 R1 siRNA-transfected cells (Fig. S2B ).
To confirm these observations, we monitored the distribution of endogenous autophagosomes and lysosomes in siRNA-transfected HeLa cells. In control and TG2-siRNA-transfected cells, LC3-labeled autophagosomes and lysosomal-associated membrane protein 1 (LAMP1)-labeled lysosomes were widely distributed in the cells and stochastically overlapped with each other (Fig. S2C) . However, autophagosomes accumulated near the nucleus in cells transfected with IP 3 R1 siRNA (Fig. S2C ). These data confirmed the observations using tfLC3 indicators that autophagy was regulated by the opposing effects of TG2 and IP 3 R1.
The IP 3 R1 Gln2746 Residue Is a Potent TG2 Substrate. To elucidate the mechanism by which TG2 inhibited IP 3 R1-mediated signaling, we performed limited digestion experiments to identify the site of TG2 modification in IP 3 R1. Calpain digestion of IP 3 R1 pretreated with TG2 revealed a marked decrease in the C-terminal 130-kDa (C130) and 85-kDa (C85) fragments but not the N-terminal 180-kDa (N180) or 100-kDa fragments (N100) ( Fig.  S3 A and B). Consistent with these observations, cross-linking by TG2 after limited digestion also resulted in a marked decrease in C130 recovery, whereas the amount of N180 was not altered by TG2 (Fig. S3C ). These results indicate that cross-linking occurs between the C130 fragments but not the residual N180 fragments. To confirm this, we performed limited digestion of BP-containing IP 3 R1 (Fig. S3 D and E) . The apparent sizes of BP-labeled bands corresponded to the C130 and C85 fragments. Further digestion confirmed that the BP-labeled bands corresponded to the C-terminal fragment. Together, these results indicated that subunit cross-linking occurred within the C130 fragments.
To precisely determine the Gln (Q) donor site for IP 3 R1 crosslinking, we performed mass spectrometric analyses. We pulled down endogenous substrates of TG2 from mouse brains by incorporation with BP. A band of ∼300 kDa was identified as mouse IP 3 R1 by in-gel digestion and mass spectrometry (MS), indicating that IP 3 R1 is a preferred substrate of TG2 (Fig. S4 A  and B) . Calculating the mass of BP, we found that the carboxylterminal peptide was exclusively modified among 63 Gln residues assigned by mass analysis (Fig. S4C) . We determined the precise modified residue in IP 3 R1 using liquid chromatography-MS (LC-MS), followed by tandem MS (MS/MS). This analysis identified one transamidation site of the Gln residue at position 2746 (Gln2746) (Fig. 4A) . Compared with the wild-type peptide, -free condition. The bar graph represents the mean + SD of peak amplitudes (control siRNA, n = 117; TG2 siRNA, n = 119). ΔR indicates changes in the fura-2 ratio in response to 3 μM ATP. ***P = 8 × 10
. a clear mass shift corresponding to BP was detected in the modified peptide (Fig. 4A) . The substrate specificity of TG2 was determined using the sequence motif QxPl (x, any; l, aliphatic amino acids) (53) . The sequence containing Gln2746 is consistent with this motif, indicating that Gln2746, but not Gln2747, is a target of TG2. Peptides containing QxP motifs at Gln524, Gln1137, and Gln1219 in mouse IP 3 R1 were detected by MS, but no BP incorporation was observed at these sites. Therefore, these Gln residues are not accessible to TG2 in the native conformation of tetrameric IP 3 R1.
The QxP motif at Gln1705 might be modified by TG2 modification; therefore, we examined the cross-linking of mutants. We generated deletion mutants of the C-terminal domain of mouse IP 3 R1 (calculated mass, 132.4 kDa, corresponding to the C130 fragment) and expressed them in COS-7 cells (Fig. 4B) . We found that the recombinant wild-type (WT) channel was crosslinked by TG2, but the deletion mutant ΔQQPA (Fig. 4C ) and the Q2746N mutant (Fig. 4D) were not cross-linked. These results indicate that the C-terminal QxP motif at Gln2746 was essential for subunit cross-linking. This motif is conserved among vertebrates including fish, birds, and mammals but not among invertebrates, suggesting that this regulation might be specific to vertebrates. The Gln2746-containing QxP motif is not conserved among other isoforms, but mouse IP 3 R2 (Gln897, Gln1221, and Gln1997) and mouse IP 3 R3 (Gln896, Gln1211, and Gln1948) also contain three QxP motifs. If these motifs are exposed and accessible to TG2, IP 3 R2/3 might also be TG2 targets.
Next, we examined whether the Gln2746-containg motif is sufficient for cross-linking by TG2. The NPQQPA peptide, but not NPNQPA, reacted with tetramethylrhodamine cadaverine (TMR-cad) to produce a cross-linked product with TG2 (Fig.  S4D) . We confirmed the structure of this purified product using MS and subsequently subjected it to a de-cross-linking reaction with TG2. Incubation of the product with both TG2 and CaCl 2 formed a product that was consistent with TMR-cad (Fig. S4E) . These data indicate that the Gln2746-containg motif is essential and sufficient for cross-linking by TG2.
Either isopeptide hydrolysis and/or deamidation by TG2 can generate a glutamate residue (E) at the position of the intrinsic Gln residue (Q) (34) . To test this possibility, we generated the antibody αE2746, which specifically recognizes deamidated IP 3 R1 (Fig. S5A) . The site-specific αE2746 antibody detected TG2-catalyzed deamidation of tetrameric IP 3 R1 in P2/P3 vesicles (Fig.  S5B) . The αE2746 antibody revealed the existence of deamidated IP 3 R1 in cerebellar IP 3 R1 (Fig. S5C) , and LC-MS analysis also confirmed the deamidated IP 3 R1 (Fig. S5 D and E) . The specificity of the αE2746 antibody was further validated using the fulllength IP 3 R1 with Q2746E mutation (Fig. 5A and Fig. S5F ).
Modification of IP 3 R1 in HD Models. Our data indicated that the modification by TG2 impaired IP 3 R1-mediated cellular processes; therefore, we hypothesized that this regulation might lead to cellular dysregulation under pathological conditions. TG2 is up-regulated in the brain in HD model mice, including R6/2 and YAC128 mice (54) (55) (56) (57) , and HD patients (49, (58) (59) (60) (61) . Therefore, we tested whether IP 3 R was modified by TG2 in these HD models.
We investigated TG2-mediated modification of IP 3 R1 in an animal model of HD R6/2, which is transgenic (Tg) for exon 1 of the human Htt gene with 120 polyQ repeats, using the specific antibody that recognizes modified Gln2746 in IP 3 R1 (Fig. 5A) . The brain P2/P3 vesicles were obtained from the cerebrum including the striatum and the cortex or the cerebellum (CB) of three litter pairs of 4-wk-old and 12-wk-old HD model mice (R6/2 Tg or WT); we observed endogenous IP 3 R1 using αE2746 and 4C11 that detects both modified and unmodified IP 3 R1. The IP 3 R1 expression levels were suppressed particularly in 12-wk-old HD mice (16, 28) ; thus, we normalized the αE2746 signal to the 4C11 signal. The relative level of the αE2746 signal was significantly higher in the brains of both 4-wk-old and 12-wk-old R6/2 Tg mice compared with WT mice (Fig. 5B) .
TG2 up-regulation has been observed in the brain and lymphocytes of patients with HD (49, 58-61); therefore, we examined a role of TG on IP 3 R activity in B-lymphocytes from HD patients. Pretreatment with a specific TG blocker (Z-DON-ValPro-Leu-OMe, ZDON) (56, 62) enhanced IP 3 R-mediated Ca 2+ release during B-cell antigen receptor stimulation by the antiIgM antibody, which evoked IICR (63) in lymphocytes from a patient with HD (Fig. 5C) . Notably, this effect was consistently observed in three individuals with HD. This indicates that in addition to the modification in the structure of IP 3 R in HD model mice (Fig.  5B) , TG modifies the function of IP 3 R in B-lymphocytes from HD patients (Fig. 5C) .
We observed the effects of the human Htt mutant on Ca 2+ signaling in other HD models. The induced expression of the full-length human Htt including 145 polyQ in PC12 cells impaired acetylcholine (ACh)-evoked Ca 2+ release under Ca 2+ -free conditions, whereas the enhanced ACh-evoked Ca 2+ increase (Fig. S6A) (Fig. S6B) . Transient expression of Htt exon1 including 60 polyQ (eHtt60Q-EGFP) or 150 polyQ (eHtt150Q-EGFP) also impaired Ca 2+ release in Neuro2a cells compared with the control (eHtt18Q-EGFP) (Fig.  S6C) , and the 3,5-dihydroxy phenylglycine (DHPG)-evoked Ca 2+ increase in eHtt150Q-EGFP-expressing neurons was lower compared with eHtt18Q-EGFP-expressing neurons (Fig. S6D) . To examine the involvement of TG2-dependent modification, we transfected Neuro2a cells coexpressing eHtt150Q-EGFP with either a Gln2746 mutant fragment (AQPA) or a Gln2746-containing fragment (QQPA). Overexpression of QQPA enhanced Ca 2+ release compared with AQPA (Fig. S6D) , suggesting the involvement of TG2-dependent modification. We also examined the Gln2746 modification in Neuro2a cells inducibly expressing Htt exon1 including 16 polyQ (eHtt16Q-EGFP) or 150 polyQ (eHtt150Q-EGFP) using the αE2746 antibody. Western blotting of endogenous IP 3 R1 (Fig. 6E) and immunostaining of the overexpressed IP 3 R1 C terminus (Fig. 6F ) demonstrate that the αE2746-detectable modification was enhanced in the Neuro2 cells with eHtt150Q-EGFP after 48-h induction compared to those with eHtt16Q-EGFP.
Discussion
The role of defective allostery in ER-resident calcium channels in subsequent cellular defects in neurological disorders remains unclear. The current study addresses this issue, demonstrating a novel allosteric mechanism-the covalent modification of IP 3 R structure and function-as well as its implications for the etiology of neurological diseases. Specifically, we discovered that TG2 in the brain regulates IP 3 R1 by catalyzing a posttranslational modification at the Gln side chain of the Gln2746 residue. Upregulation of TG2 enhanced the Gln modification of IP 3 R1, and TG2 suppressed IP 3 R1-mediated Ca 2+ signaling and subsequent cellular processes. Modification of Gln2746 and IP 3 R1 function was observed in HD models and B-lymphocytes from HD patients; these results therefore suggest a novel mechanism linking the activation of brain TG to the control of IP 3 R-mediated Ca 2+ signaling in HD. Based on these results, we propose a general model for the progressive brain dysfunction observed in brain pathogenesis that involves aberrant IP 3 R signaling.
An important point in this study is the identification of TG2 as a chronic regulator of IP 3 R1 structure and function. This finding has broad implications for pathological neuronal function and degeneration because it links TG2 functions in cellular differentiation, cellular stress, and inflammation (34, 35) to the chronic defects in Ca 2+ signaling. Numerous literatures have demonstrated that TG2 is up-regulated in various diseases including HD (49, 54, 55, 59-61), AD (37, 38, 40, 42, 43, 45) , and PD (39, 44) . The splicing mechanism (67, 68) and stress-dependent inductions (34, 35, (69) (70) (71) (72) are considered to elucidate the up-regulation, and the increased Ca 2+ levels observed in many diseases (4, 17-22) are also competent to trigger TG2 activation. The Ca 2+ -dependent activation of TG2 inhibits the IP 3 R1-mediated Ca 2+ release, as revealed in the current study; thus, this enzymatically allosteric modulation should primarily contribute to a negative feedback mechanism to maintain homeostatic control of intracellular Ca 2+ levels. However, this modification subsequently would have a chronically negative effect on Ca 2+ signaling, because it is much more static than noncovalent allosteric modulators required for the control of rapid and dynamic Ca 2+ signaling such as Ca 2+ oscillation. Therefore, the TG2-dependent allosteric modulation should chronically set in motion cascades of defective signaling related to pathological states; up-regulation of TG2 may disrupt the IP 3 R1-mediated plasticity of neuronal signaling (3, (10) (11) (12) and the homeostatic control of cellular processes including mitochondria energy production (23), autophagy regulation (24-27), ER stress (28), and others (29) (30) (31) and ultimately increases cellular stress, resulting in further TG2 up-regulation proceeding a vicious cycle. Given the widespread brain expression profiles of TG2 and IP 3 R1, we propose that the mechanism described in this study might potentially serve as a general principle for many other diseases of the brain or other tissues in which TG2 is up-regulated by a disease-initiating agent. In this study, we assume that the disease-initiating agent is the mutant Htt; future studies are required to examine whether other disease-initiating agents such amyloid proteins in AD and α-synuclein in PD also would cause chronic TG2 activation, resulting in IP 3 R modification and aberrant calcium signaling, and suggesting its presumable role in brain dysfunctions including cognitive declines occurs frequently during the prodromal states of these neurodegenerative diseases (73) (74) (75) (76) (77) . This study revealed that the covalent modification by TG2 results in three alternative states, as shown in Fig. 6 ; thus, the other roles of TG2 in Ca 2+ signaling are also conceivable. TG2 inhibits IICR activity by both cross-linking and steric hindrance around Gln2746 (Fig. 2) , whereas functional analysis of Q2746E indicates that deamidation of IP 3 R1 suppresses TG2-mediated inhibition (Fig. S6G ). All potential modifications are shown in the schematic diagram, but the overall activity of a single channel would depend significantly on the relative number of crosslinked isopeptide bonds, amine incorporations, and deamidation in the tetramer. Acute increases in Ca 2+ levels cause subunit cross-linking in neuroblastoma and glioblastoma cells (Fig. 1E) , whereas amine incorporation and deamidation were observed in resting cells and brain tissues without stimulation by increasing Ca 2+ concentrations (Fig. 5B and Figs. S5 C-E and S6 H and I). The deamidation reaction by TG2 is dependent on pH (78) and substrate affinity (79); therefore, the relative abundance of these three modifications is presumably determined by the cellular state and the conformation around Gln2746. These irreversible processes would contribute to chronic changes in homeostasis of Ca 2+ signaling and subsequent cellular processes, whereas the TG2-resistant states including the small amine-containing IP 3 R1, such as BP incorporation shown in Fig. 2C and/or the deamidated IP 3 R1 shown in Fig. S6G , might contribute to Ca 2+ -dependent cell death, including apoptosis (2, 17), due to the lack of negative feedback regulation by Ca 2+ . Although deletion of the C-terminal 12 amino acids has no effect on IICR (80), binding of the specific monoclonal antibody 18A10 (81) and GIT1 to this region inhibits IICR (82) , similar to the BP-avidin complex in this study. Because both IgG and GIT1 form bulky architectures, these observations are consistent with our conclusion that large molecules such as avidin but not small moieties such as BP interfere with configuration changes by steric hindrance. IICR is regulated by binding of the C-terminal region near Gln2746 by various proteins governing cellular fate-for example, Bcl-X L , Bcl-2, cytochrome c, HAP1, and Htt (4, 5, 17, 18) ; thus, we speculate that the IP 3 R1 C terminus might act as a signaling hub whose structure affects cellular processes by regulating the subunit configuration by steric hindrance. Considering the direct activation of IP 3 R1 by the Htt mutant (18) , the net activity of IP 3 R1 may be comprehensively determined by the Htt mutant and TG2 in HD. The impairment of Ca 2+ release by eHtt150Q-EGFP , and HD3 correspond to GM5560, GM6773, and GM4830, respectively. The peak amplitude was calculated as the difference between the mean value before stimulation and the peak value during stimulation.
was more potent than Htt145Q-myc ( Fig. S6 B and C) , consistent with higher TG2 activities in R6/2 than YAC128 mice expressing the full-length Htt mutant (55, 57) and the sensitized Ca 2+ increase in YAC128 mice more than shortstop mice expressing Htt exon1/2 (64). The poly-Gln repeat of the Htt mutant is a favorable substrate of TG2 (41); thus, the possibility of substrate competition and steric hindrance around Gln2746 is also interesting. Thereby, we suggest that the prevalence of fulllength Htt mutant and TG2 modulations on IP 3 R1 may determine the total net activity of Ca 2+ signaling from the ER and the pathological states in HD-that is, the prodromal decline of neural signaling or the degeneration by apoptosis.
The first insight into the mechanism underlying the coupling between the IBD and the channel domain by IP 3 -evoked structural changes was described more than two decades ago (83) . From our early EM studies of negatively stained IP 3 R1 using heparin-gold labeling, we proposed a long-range coupling of IBD to the channel domain by Ca 2+ -dependent structural changes (84) (85) (86) . However, direct binding of the IBD to the channel domain was postulated, and a model was proposed in which an N-terminal suppressor domain directly binds a loop between putative transmembrane helices (87) (88) (89) (90) . Recently, highly improved cryo-EM reconstruction was reported (9) , and by fitting calculations using X-ray structures (7, 8) , it was concluded that direct interaction of the IBD with the channel domain is unlikely (8) . However, because the X-ray structure of the IBD is limited to only 5% of each tetramer, which is equivalent to 20% of each subunit, the role of the other domains in channel gating remains unclear (91) . Here, we show new evidence demonstrating that configuration changes outside the IBD are required for channel activation (Fig. 6 ). Our data are consistent with the conclusion that the Gln2746 in the C-terminal tail is proximal to the neighboring IP 3 R1 subunit, and TG2 covalently tethers Gln2746 to the adjacent subunit by the Gln-Lys isopeptide bond that locks the channel in a closed configuration (Fig. 6) . Notably, our BP incorporation experiments indicate that the isopeptide bond occurs outside the IBDs without impairing the intrinsic structures required for IP 3 binding and Ca 2+ permeation (Fig. 2 B-D) . IP 3 R1 function was not inhibited by transamidation of a small molecule such as BP; however, the subsequent addition of a bulky molecule such as avidin completely blocked receptor function (Fig. 2 B-D) , indicating that steric hindrance near Gln2746 is crucial. We propose that an "allosteric coupling domain" in the C-terminal 130-kDa region (C130) exists between the IBD and the transmembrane domains to couple the IBD to the channel and that configuration changes in this domain are required for channel activation (Fig. 6) . The EcoRI fragment-encoded short domain (ES; amino acids 2216-2749) of IP 3 R1 is sufficient for tetramer formation (92) , but the channel in the ES tetramer is always open (93) . Therefore, the allosteric coupling domain presumably keeps the channel closed, and the transition to the open configurations could revert to the default channel state that constitutively permeates Ca 2+ -for instance, the leaky channel assembled from ES domains.
What is the key mechanism regulating the allosteric transitions during channel activation? Two intrinsic determinants stabilizing the subunit configurations can be considered a priori-IP 3 and Ca
2+
-because channel activation requires both IP 3 and Ca
. In fact, the recent X-ray structures of the IBD indicate that conformational changes occur upon IP 3 binding (7, 8) ; our group and others have demonstrated Ca 2+ -induced structural changes (84, 85, 94, 95) . Fluorescence resonance energy transfer (FRET) analysis of recombinant IP 3 Rs also showed reversible structural changes induced by physiological concentrations of IP 3 and Ca 2+ (96) . Considering these observations and our current data, we propose that structural changes by IP 3 and Ca 2+ determine the configuration of the allosteric coupling domain. Given the Ca 2+ -sensor site at E2100 (32) and the deletion site in opisthotonos mice (33) are located in this domain, these allosteric sites presumably control subunit configurations within this domain. These ligandsthat is, IP 3 , Ca
, and ATP-might confer a predominantly open configuration by noncovalent binding, but the covalent Gln-Lys isopeptide bonds and steric hindrance around Gln2746 are more energetically stable; therefore, these modifications can robustly and chronically lock the closed subunit configuration.
In summary, we identified TG2 as an IP 3 R1-modifying enzyme that irreversibly controls the essential function of IP 3 R1 in Ca 2+ -signaling and subsequent cellular processes whose homeostasis is crucial for cellular fate and uncovered the allosteric mechanism by which IP 3 R channel activation is controlled by ligand binding. Many functional proteins undergo allosteric regulation; therefore, understanding allosteric mechanisms can elucidate the mechanisms underlying functions of these proteins and pave the way for drug design (1) . This is the first demonstration, to our knowledge, of IP 3 R1 allosteric transitions locked by TG2-catalyzed cross-linking, and these observations might provide a new framework for TG2-dependent enzymatic regulation of ligandgated ion channels and allosteric proteins similar to IP 3 R1.
Materials and Methods
Cell Culture. SH-SY5Y, U87-MG, HeLa, and COS-7 cells were cultured in DMEM containing 10% (vol/vol) heat-inactivated FBS, 50 U/mL penicillin, and 50 μg/mL streptomycin. Human B-lymphocytes from patients with HD were obtained from the Coriell Institute (GM5560, GM6773, and GM4830) and cultured in RPMI medium 1640 containing 10% (vol/vol) heat-inactivated FBS, 50 U/mL penicillin, and 50 μg/mL streptomycin. All cells were maintained in 5% (vol/vol) CO 2 at 37°C. The differentiation medium supplemented with 20 μM RA was replaced every 48 h for the SH-SY5Y and U87-MG cells. All of the animals were ethically treated according to the guidelines of the Animal Experiments Committee of the Institute of Physical and Chemical Research (RIKEN) Brain Science Institute.
Transfection of siRNAs or Plasmids. The siRNAs and human negative controls were purchased from B-Bridge. The nucleotide sequence of the TG2 siRNA was ggucaaugccgacguggua. IP 3 R1 knockdown was performed as described previously . The Q-donor at the C terminus is located in close proximity to the K-donor region of the neighboring subunit. We propose reversible configuration changes between the closed and open states in tetrameric IP 3 R1. TG-catalyzed transamidation causes covalent intersubunit cross-linking, which locks the closed configuration. A large molecule such as avidin but not a small moiety such as BP inhibits the motion by amine incorporation. Gln2746 of IP 3 R1 is deamidated by TG2 and converted into a glutamate residue that is resistant to TG2-mediated inhibition. (28) . The siRNA and ptfLC3 were transfected in HeLa cells using Lipofectamine 2000 (Invitrogen) and TransIT (Mirus) transfection reagents, respectively.
Preparation of P2/P3 Fractions. Mouse brains were washed extensively with chilled PBS and were then homogenized in a homogenate buffer (pH 7.5) composed of 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes)/sodium hydroxide (NaOH), 0.32 M sucrose, 1 mM ethylene diamine tetraacetic acid (EDTA), 2 mM Tris(2-carboxyethyl)phosphine (TCEP), and protease inhibitors (0.2 mM phenylmethylsulfonyl fluoride, 10 μM leupeptin, 10 μM pepstatin A, and 10 μM E-64). The homogenates were centrifuged at 800 × g for 5 min at 4°C, and the resultant supernatants were subjected to ultracentrifugation at 105,000 × g for 60 min at 2-4°C as previously described (97) . The precipitates were suspended in resuspension buffer ResB (pH 7.5), containing 50 mM Hepes-NaOH, 150 mM NaCl, 1 mM EDTA, 2 mM TCEP, and protease inhibitors. The supernatant obtained after ultracentrifugation was used as the cytosolic fraction. The protein concentrations in the solution were estimated, adjusted to 3 mg/mL using ResB, and the samples were then quickly frozen in liquid nitrogen for storage until use in various experiments.
Analysis of Intersubunit Cross-Linking Within IP 3 R1 by Electrophoresis. We estimated the cross-linking between IP 3 R1 subunits using 1% AGE. The samples containing mouse cerebellar P2/P3 proteins (0.75-2.25 μg) were loaded in individual wells. Agarose was dissolved in a buffer containing 0.1% SDS using a microwave device. The agarose was heated and then gently mixed by manual rotation. The 1% agarose solution was poured into an acrylic tray (Nihon Eido) in which a 26-lane comb was placed. After 30 min at room temperature, the apparatus was filled with the electrolyte buffer, and the comb was carefully removed. Electrophoresis was performed at 100 V for 1-2 h. Immediately following electrophoresis, the agarose gels were placed in transfer buffer for 30 min. The separated proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore). IP 3 R1 was detected using the 4C11 monoclonal antibody as described previously (28, 97) . A molecular marker was prepared by cross-linking bovine thyroglobulin with 1 mM 1,8-bis-maleimido-diethyleneglycol overnight at 4°C.
Measurement of Ca
2+ Release Activity of IP 3 R1. We loaded fura-2AM (Dojindo) into HeLa cells and B-lymphocytes by incubation with 5 μM fura-2AM in balanced salt solution (pH 7.4) containing 115 mM NaCl, 5.4 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 20 mM Hepes, and 10 mM glucose for 30 min at room temperature, and performed Ca 2+ imaging using inverted fluorescence microscopy with a 20× objective lens (S Fluor 20× N.A. 0.75) (Nikon) and AQUACOSMOS (Hamamatsu Photonics) to obtain F340/F380 ratio images as described previously (28, 98) . For measurements of IICR, the P2/P3 membranes (3 mg/mL protein) of mouse cerebella were washed three times with a buffer (pH 7.4) containing 50 mM Hepes-KOH, 110 mM KCl, 10 mM NaCl, and 5 mM KH 2 PO 4 . The washed 10-μL P2/P3 membranes (2 mg/mL protein) of the cerebella were added to 287 μL of a buffer containing 1 mM 2-mercaptoethanol, 1 μM CaCl 2 , and 0.2 μM fura-2 in a cuvette. To introduce Ca 2+ into P2/P3 membrane vesicles, we added 3 μL of 100 mM Mg-ATP to the cuvette with stirring. Ratiometric measurement of fura-2 was performed at 30°C using a CAF-110 (Jasco) or an F-2500 spectrofluorometer (Hitachi).
Analysis of Autophagosome Dynamics by Fluorescence Microscopy. We used ptfLC3 plasmids (52) expressing mRFP-GFP-LC3 to monitor autophagic processes in living cells. Cells plated in a 35-mm glass-bottomed dish were transfected with siRNA in Lipofectamine 2000 transfection reagent (Invitrogen) and then with 1 μg ptfLC3 by TransIT transfection reagent (Mirus) 6 h after the siRNA transfection. We observed GFP and RFP fluorescence signals in living cells under an FV1000D confocal microscope (Olympus) with a stage top incubator in 5% CO 2 at 37°C.
Affinity Purification of TG2 Substrates. We incubated the reaction solution containing the P2/P3 fractions (1 mg/mL protein), 50 mM Hepes-NaOH (pH 7.5), 150 mM NaCl, 10 mM BP, 1 mM EGTA, 2 mM CaCl 2 , and 30 ng/mL TG for 30 min at 37°C. The mixture was centrifuged at 20,000 × g for 30 min at 4°C, and the pellets were washed with 50 mM Hepes-NaOH (pH 7.5). The proteins were solubilized with 1% (wt/vol) 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) and mixed with avidin-agarose. After washing three times with the 1% CHAPS-containing Hepes buffer, the biotin-containing proteins bound to avidin-agarose were subjected to SDS/ PAGE and were detected by Coomassie brilliant blue (CBB) staining or Western blotting analysis. The CBB-stained band was excised, digested using an in-gel digestion protocol, and analyzed by MS using MALDI-TOF MS (ABI).
Specific Antibody Against Modified IP 3 R1. To examine the status of Gln2746 in mouse IP 3 R1, a deamidated peptide (PPHMNVNPEQPA) corresponding to amino acids 2738-2749 was synthesized and conjugated to keyhole limpet hemocyanin via a cysteine added to the N terminus of the peptide. Japanese white rabbits were immunized with these peptides. The resulting polyclonal antibody was first applied to an affinity resin immobilized with a control peptide (PPHMNVNPQQPA) via cysteine added to the amino terminus, and the flow-through was applied onto a resin immobilized with the deamidated peptides. The specific antibody against the deamidated peptide was eluted with 100 mM glycine-HCl buffer (pH 2.5). To verify the specificity of the antibodies, we prepared recombinant IP 3 R1, which was expressed as an EGFP-fusion protein (28) . The PCR product was inserted into EGFP-IP 3 R1-containing pcDNA3.1 vector with EcoRI and XhoI. Mutation of the Gln residue at the amino acid position of 2746 was confirmed by sequence analysis using an ABI 3730xl automatic sequencer. To confirm the specificity of the E2746 antibody, the C-terminal fragment of IP 3 R1 (66 amino acids) was subcloned into the bacterial expression vector pGEX-6p (GE Healthcare) using EcoRI and SalI. Quantification of modified or native IP 3 R1 was performed by densitometric analysis of Western blots using Image J software (National Institute of Health).
Statistical Analysis. All probability calculations were performed using unpaired and two-tailed Student t tests. The significance after multiple comparisons was estimated by the Bonferroni method or by Dunnett's method. For all data, no statistics were used for predetermination of the sample size, randomization, or blinding.
